english.prescrire.org > Prescrire International > N°196 - September 2018

n°196

September 2018

Issue Contents
Editorial

Free  Profit and loss

p.199

New Products


Baricitinib (Olumiant°) and rheumatoid arthritis

p.201-205
Oral administration is not a sufficient advantage

Lacosamide (Vimpat°) from 4 years of age

p.206

Oral cladribine (Mavenclad°) and multiple sclerosis

p.207

INN Common stem: sulfa-

p.207

Lenalidomide (Revlimid°) and multiple myeloma

p.208-210
Maintenance therapy after autologous transplantation: conflicting results

Telithromycin: a welcome market withdrawal

p.210

Adverse Effects


Congenital malformations: are we underestimating the role of teratogenic agents?

p.211

Free  Silver sulfadiazine cream: disproportionate adverse effects

p.212

Vemurafenib: Dupuytren's contracture

p.213

Zoledronic acid: osteonecrosis of the hip, femur and humerus

p.213

Finasteride in alopecia: a disproportionate risk of depression or suicidal thoughts

p.214

Reviews


Smoking cessation

p.215-217
Varenicline: safer to make repeated attempts with nicotine

Drug-eluting coronary stents

p.217-218
Combining two antiplatelet drugs: for a few months, but dangerous beyond one year

Low back pain

p.219
No demonstrated efficacy of systemic cortico­steroids

Type 2 diabetes

p.219-220
Canagliflozin: minimal cardiovascular benefit and an increase in amputations and ketoacidosis

David Young

p.220
A translator who helped expand Prescrire's international reach

Outlook


More cases of thyroid cancer: mainly due to overdiagnosis

p.221-222

Pharmaceutical companies: profit above all else

p.222-223

Masthead


Free  Masthead

p.198

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe